The rate of granulocytic expansion could be associated with disease-specific factors such as genomic alterations in myeloid driver genes, which have been shown to occur in 26% of CP CML patients and to associate with TFR [30]. This evidence concerns the gene TFRC and chronic myelogenous leukemia, BCR-ABL1 positive.